AHIP Hits Hard On Cost Issue, Using Hepatitis C Drug As Example
Reuters: U.S. Health Insurers Say Gilead Hepatitis C Drug Too Costly
The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels. The latest salvo in the war on escalating U.S. healthcare costs came from AHIP - America's Health Insurance Plans - and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc. (5/20).